Barcelona, Spain, and Tokyo, July 27, 2021 – Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines with a more than 100-year track record of contributing to the health and well-being of people around the world, and OrphanPacific, Inc., which provides drugs for rare diseases and disorders in Japan, today announced the beginning of the commercialization of Lynspad™ (intravenous infusion 1000mg), an alpha-1 proteinase inhibitor to treat severe alpha-1 antitrypsin deficiency (AATD) in the country.

Please visit OrphanPacific’s website for more details of the press release:

English Press Release: Grifols, OrphanPacific start commercializing Lynspad™ [alpha-1 proteinase inhibitor] to treat alpha-1 antitrypsin deficiency